 | Esperion's Multiple Positives, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - February 20 at 9:19 AM |
 | BTIG Research Raises Esperion Therapeutics (NASDAQ:ESPR) Price Target to $90.00
www.americanbankingnews.com - February 19 at 8:58 AM |
| Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Post Quarterly Sales of $970,000.00
www.americanbankingnews.com - February 17 at 2:06 AM |
| Esperion Therapeutics Inc (NASDAQ:ESPR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 16 at 12:27 PM |
| Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Announce Earnings of -$2.71 Per Share
www.americanbankingnews.com - February 15 at 6:14 PM |
| Esperion Therapeutics (NASDAQ:ESPR) Downgraded to Neutral at Citigroup
www.americanbankingnews.com - February 14 at 12:51 PM |
 | Noteworthy Friday Option Activity: ESPR, YUMC, VSAT
www.nasdaq.com - February 7 at 7:51 PM |
| Chardan Capital Reaffirms Hold Rating for Esperion Therapeutics (NASDAQ:ESPR)
www.americanbankingnews.com - February 1 at 6:31 AM |
| Esperion: Recent Pullback Offers Buying Opportunity Ahead Of February PDUFA Dates
seekingalpha.com - January 31 at 6:17 PM |
 | European Advisory Group Backs Esperion's Cholesterol Drugs
www.fool.com - January 31 at 1:10 PM |
| European advisory group back Esperion's bempedoic acid
seekingalpha.com - January 31 at 8:09 AM |
 | Esperion Announces Positive CHMP Opinion for the...
www.benzinga.com - January 31 at 8:09 AM |
| European advisory group backs Esperion combo tablet for high cholesterol
seekingalpha.com - January 31 at 8:09 AM |
 | Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
finance.yahoo.com - January 31 at 8:09 AM |
| Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
finance.yahoo.com - January 31 at 8:09 AM |
| One Thing To Remember About The Esperion Therapeutics, Inc. (NASDAQ:ESPR) Share Price
finance.yahoo.com - January 27 at 5:42 PM |
| Target N. V. Biotech Purchases 20,000 Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) Stock
www.americanbankingnews.com - January 27 at 3:46 PM |
| Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 5:44 PM |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - January 3 at 4:50 PM |
| Esperion (ESPR) Almost Doubled In 2019, What Awaits The Stock In 2020?
www.nasdaq.com - January 3 at 6:16 AM |
| 4 Healthcare Stocks With FDA Approvals on the Horizon
www.fool.com - December 12 at 12:25 PM |
| Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ?
finance.yahoo.com - December 12 at 12:25 PM |
| Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - December 6 at 3:02 PM |
| Can Cannabis 2.0 Kickstart Marijuana Stocks?
www.fool.com - December 6 at 10:01 AM |
| Esperion's Promising Drugs Under Review, Funds a Concern
finance.yahoo.com - November 28 at 12:38 PM |
| Notable Monday Option Activity: ESPR, DY, SPOT
www.nasdaq.com - November 18 at 5:53 PM |
| Esperion Therapeutics Breaks Above 200-Day Moving Average - Bullish for ESPR
www.nasdaq.com - November 18 at 12:53 PM |
| Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
finance.yahoo.com - November 17 at 7:25 PM |
| Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
finance.yahoo.com - November 12 at 2:56 PM |
| President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR)
finance.yahoo.com - November 10 at 8:48 AM |
| Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?
finance.yahoo.com - November 9 at 1:11 PM |
| Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?
finance.yahoo.com - November 9 at 1:11 PM |
| Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 6 at 2:56 PM |
| Esperion Therapeutics EPS misses by $0.57, misses on revenue
seekingalpha.com - November 6 at 7:59 AM |
| Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
finance.yahoo.com - November 6 at 7:59 AM |
| Esperion Therapeutics Q3 2019 Earnings Preview
seekingalpha.com - November 5 at 7:05 PM |
| Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
finance.yahoo.com - November 4 at 7:52 AM |
| Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
finance.yahoo.com - October 29 at 8:26 AM |
| Should You Buy Esperion Therapeutics, Inc. (ESPR)?
finance.yahoo.com - October 28 at 6:24 PM |
| Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
finance.yahoo.com - October 25 at 1:48 PM |
| Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation
finance.yahoo.com - October 5 at 12:35 AM |
| Esperion Therapeutics: Low Risk And Primed For Substantial Growth
seekingalpha.com - October 4 at 2:34 PM |
| Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation
finance.yahoo.com - October 4 at 2:34 PM |
 | Monday 9/9 Insider Buying Report: ACHC, ESPR
www.marketwatch.com - September 10 at 5:54 AM |
| Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares
finance.yahoo.com - September 7 at 2:38 PM |
| Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - September 7 at 2:38 PM |
| Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
finance.yahoo.com - August 30 at 8:02 PM |
| Esperion's bempedoic acid successful in mid-stage study in type 2 diabetics with high cholesterol
seekingalpha.com - August 29 at 11:45 AM |
| Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
finance.yahoo.com - August 29 at 11:45 AM |
| Esperion's Drugs in Review Hold Potential, Funds a Concern
www.nasdaq.com - August 27 at 9:09 AM |
